ABSTRACT
Administration of protein C concentrates in patients without congenital deficit: a systematic review of the literature Introduction Sepsis is a highly complex process triggered by the release of numerous mediators that activate various defense systems, including the coagulation pathway. Severe sepsis and septic shock are life-threatening medical emergencies and are among the most significant challenges in critical care. Low endogenous protein C (PC) levels are related to poor prognosis in patients with sepsis.
(1) If low circulating PC levels could be restored to normal ones by infusion of exogenous PC, morbidity and mortality from sepsis might be reduced. PC is a vitamin K-dependent serine protease produced by the liver, present in the blood as a zymogen activated by thrombomodulin, a complex of thrombin and endothelial thrombin receptor, situated on the membrane of endothelial cells. Activated protein C (APC) exerts an anticoagulant effect and has anti-inflammatory and pro-fibrinolytic properties, preventing and reversing microvascular thrombus formation. (2) Survival Sepsis Campaign Guidelines recommend treatment strategies such as early-goal directed therapy and the use of recombinant human APC (rhAPC). (3) Recently, the PROWESS SHOCK trial did not confirm the benefits of drotrecogin alfa (rhAPC), therefore the drug was withdrawn from the market because of limited efficacy and the presence of side effects (bleeding). Protein C concentrates (PCc) administration might be a useful alternative. (4) The safety and efficacy of intravenous or subcutaneous PCc for long-term prophylaxis in congenital PC deficiency is established since the year 1991. (5) Few authors have tested the utility of PCc in young patients with purpura fulminans and/or meningitis and few reports exist on the use of PCc as an alternative treatment to rhAPC in adult patients affected by sepsis or septic shock, in which rhAPC was contraindicated by a high risk of bleeding. We previously reviewed (6-8) the published experience with PCc in 66 adults (6) (7) (8) (9) (10) (11) (12) (13) (14) and 118 children (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) without congenital defects. Considering the market withdrawal of rhAPC, the recent publication of further case series (26) (27) (28) (29) and the presence of reports (30) (31) (32) (33) that were not identified in the previous reviews, we decided to update the systematic review and concisely summarize the overall results.
Materials and methods

Search Strategy
BioMedCentral, PubMed, Embase and the Cochrane Central Register of Clinical Trials were searched for pertinent studies (updated October 1 st , 2012) by three investigators. The search included the following terms: "protein C concentrate" or "protein C zymogen" or "Ceprotin". Further searches involved conference proceedings from pertinent congresses. The references of retrieved articles were carefully checked. No language restriction was enforced. Study Selection The search included the following terms: "protein C concentrate" or "protein C zymogen" or "Ceprotin". Identified citations were assessed on the basis of the title and abstract by two investigators; disagreement was solved by consensus, with the supervision of a third investigator. Potentially eligible studies were retrieved in full. Relevant studies were included in this systematic review of whether they met the following inclusion criteria: a) administration of PCc; b) study performed in adult or pediatric patients; c) excluding congenital PCc deficiency. Data Abstraction and Study Characteristics First author, year of publication, study design, number of patients, patient population, clinical setting, mortality, bleeding and number of amputations were independently extracted by two investigators.
Results
The systematic search initially identified a total of 6.335 titles (figure 1). Excluding 4.758 non-pertinent titles, we retrieved in complete form and assessed 1.577 studies according to the selection criteria. Excluding 1.548 non-pertinent abstracts, and 3 (34-36) were excluded because the data were already published in previous manuscripts, a total of 28 studies was finally selected, all of which described the administration of PCc in adult and pediatric populations without congenital deficits. The details of the 28 studies are reported in table 1. A total of 340 patients (232 children and 108 adults) was included and the overall mortality rate was of 20,6% (70 patients). Only two studies were randomized (20, 28) while the others were case reports or case series, the largest study reporting 94 pediatric patients with purpura fulminans. (29) The studies were published between 1993 and 2012, including mainly septic patients (94%). Sepsis was associated with meningitis, purpura fulminans, and disseminated intravascular coagulation in most cases. All papers but one (29) reported normalization of inflammatory markers and/or of coagulation abnormalities and/or improved outcome. In 233 patients with purpura fulminans and/or meningitis, 26 amputations were described (11%). One mild allergic reaction was reported as related to the study drug. No other adverse event related to PCc was reported among 340 patients. Bleeding was reported as a complication only in two papers, (20, 29) but the authors specified that it was not related to PCc administration. A randomized study performed in children described a mild gastrointestinal hemorrhage occurred in a patient who had severe disseminated intravascular coagulation (DIC) and died of septic shock one day later. (20) Veldman in his case series described two cases of bleeding: one patient developed epistaxis six hours after PCc administration, the other developed hemorrhage from the throat and the nose immediately after a difficult endotracheal intubation; both patients received the next dose of PCc without complications. (29) 
Discussion
Protein C concentrates administration has been safely reported in more than 300 patients without congenital PC deficiency. Most septic patients with or without meningitis had a normalization of laboratory findings after PCc administration. When authors used a severity-ofdisease classification system, baseline scores generally indicated an expected mortality (21-60%) higher than the overall observed mortality (20.6%). All but three studies (13, 32, 33) were of poor quality (abstract) and two thirds of the population was represented by children. During severe sepsis, there is a reduction in PC concentration; PC correlates with increased morbidity and mortality.
(1) Furthermore, in neonates PC levels reach the lower limit of normal adult levels (60-70%) around 6-12 months of age, (37) thereby increasing the risk of coagulopathy in the pediatric septic population. Recombinant human APC was always contraindicated in children and therefore majority of the manuscripts of PCc in the literature concerns the pediatric population. The published reports can be aggregated into three main groups: a) sepsis and septic shock (12 studies with 80 patients) b) purpura fulminans and/or meningitis (14 studies with 233 patients); c) DIC (2 studies with 27 patients).
A total of 12 studies (including 26 children and 54 adults) described sepsis or septic shock patients treated with PCc: 14 patients died; 5 children (19% mortality) and 9 adults (17% mortality). The largest case series about PCc in sepsis has been published by Baratto et al. (7) They described the efficacy and safety of PCc to restore physiological values in 20 adult patients with severe sepsis or septic shock having clinical contraindications to treatment with rhAPC. Crivellari et al. (6) described their experience with the use of PCc in 9 adult patients with sepsis induced double organ failure after cardiac surgery. A pilot study (28) has reported the preliminary findings on the effect of PCc on microcirculatory blood flow in adult septic shock patients. Protein C concentrates administrations in patients with purpura fulminans and/ or meningitis were described in 14 studies for a total of 233 patients (only 28 of them adults). Meningococcemia is the major infective cause of purpura fulminans, a devastating complication of uncontrolled systemic inflammation. It is characterized by thrombocytopenia, petechiae, and ecchymoses together with disseminated thrombosis of small vessels, resulting in tissue hypoperfusion, imminent peripheral gangrenes, and is associated with high incidence of amputations, skin grafts and death. 
Limitations
The main limitation of this systematic review is the poor quality of the included studies: all but two are non-randomized control trials (RTC).
Conclusions
Protein C zymogen caused one mild allergic reaction and no bleeding in 340 patients with sepsis, purpura fulminans or DIC. Purpura fulminans in children is the most validated setting for the use of PCc in patients without congenital PC deficits, even if there is no randomized evidence to support survival benefits. Adult septic patients have a normalization of laboratory findings and a less than predicted mortality when receiving PCc, but case match and RCTs are still missing.
